ResultsIQ

ResultsIQ › Latest results › SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited Q4 FY26 results deck summary

NSE: SMSPHARMA · BSE: 532815

Results deck of 23 May 2026, summarised by AI from the filing.

FY26 PAT up 48% YoY to ₹102 cr; ₹280 cr capex programme on track for completion by FY27

Key takeaways

  1. FY26 PAT Full-year PAT up 48% YoY to ₹102 cr, including share of profit of associate company VKT Pharma
  2. Capex ₹280 cr capex programme on track for completion by FY27
  3. EBITDA margin FY26 EBITDA margin up 155 bps YoY to 19%
  4. Growth driver Backward integration and mix drove FY26 PAT growth
  5. Risk Dependency on China for raw material

Original filing on BSE

SMS Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹207 cr (+6% year on year), EBITDA ₹41.0 cr (+5% year on year), PAT ₹20.9 cr (+5% year on year), EBITDA margin 19.8% (−11 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹238 cr (−4% year on year), EBITDA ₹39.9 cr (−5% year on year), PAT ₹32.7 cr (+64% year on year), EBITDA margin 16.8% (−16 bps). Score 32 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 16 bps year on year. Consolidated profit +64% but standalone 0%. Profit rose ₹12.7 cr on a year ago, more than the ₹3.0 cr it added the year before. Share price after the results: −11.1% in 28 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹210 cr (+22% year on year), EBITDA ₹43.7 cr (+32% year on year), PAT ₹23.5 cr (+30% year on year), EBITDA margin 20.7% (+167 bps). Score 65 of 100, Above trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 167 bps year on year. Revenue fell 13% from last quarter. Profit rose ₹5.5 cr on a year ago, against ₹7.0 cr the year before. Share price after the results: +20.7% in 30 days (Nifty 500: −5.9%).
  • Q2 FY26: Revenue ₹242 cr (+23% year on year), EBITDA ₹49.0 cr (+48% year on year), PAT ₹25.0 cr (+79% year on year), EBITDA margin 20.3% (+350 bps). Score 80 of 100, Above trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was well above it. EBITDA margin rose 350 bps year on year. Revenue rose ₹45.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: +10.6% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹196 cr (+20% year on year), EBITDA ₹39.0 cr (+15% year on year), PAT ₹20.0 cr (+25% year on year), EBITDA margin 19.9% (−83 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 83 bps year on year. Revenue fell 21% from last quarter. Revenue rose ₹32.0 cr on a year ago, more than the ₹29.0 cr it added the year before. Share price after the results: +8.9% in 30 days (Nifty 500: +1.9%).
  • Q4 FY25: Revenue ₹248 cr (+1% year on year), EBITDA ₹42.0 cr (+24% year on year), PAT ₹20.0 cr (+18% year on year), EBITDA margin 16.9% (+311 bps). Score 44 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin rose 311 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −5.9% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹173 cr (+7% year on year), EBITDA ₹33.0 cr (+10% year on year), PAT ₹18.0 cr (+64% year on year), EBITDA margin 19.1% (+44 bps). Score 35 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 44 bps year on year. Revenue fell 12% from last quarter. Profit rose ₹7.0 cr on a year ago, against ₹7.0 cr the year before.
  • Q2 FY25: Revenue ₹197 cr (+18% year on year), EBITDA ₹33.0 cr (+18% year on year), PAT ₹14.0 cr (+17% year on year), EBITDA margin 16.8% (−2 bps). Score 60 of 100, In line with trend. EBITDA margin was flat year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

SMS Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.